Skip To Main Content
Donavyn Coffey on Muck Rack

Donavyn Coffey

Verified
Kentucky
As seen in: MSN, MSN Australia, MSN Ireland, MSN UK, Yahoo Life, Business Insider, Business Insider Singapore, TIME, WebMD, Yahoo Canada and
Kentuckian | writing about all things health and food | bylines @Wired @TeenVogue @Self @sciam | @fulbrightprgrm alum|
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Donavyn

Contact Donavyn, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Trump calls for some childhood vaccines be split into smaller doses

|
By Donavyn Coffey Verified
| Fierce Pharma Verified
The White House is threatening yet another change to the childhood vaccine schedule in line with Secretary of Health and Human Services secretary Robert F. Kennedy Jr.’s MAHA agenda.
Open in Who Shared Issue with article?

IntraBio's Aqneursa scores expansion, now the first treatment for rare ataxia

|
By Donavyn Coffey Verified
| Fierce Pharma Verified
IntraBio is on a roll with its expansion plans for chemically altered amino acid, Aqneursa. The Texas-based pharma just secured FDA approval to expand the label of Aqneursa, which is now the first treatment indicated for a rare and prematurely fatal neurodegenerative disease called ataxia-telangiectasia (A-T). The positive ruling was based on data from IntraBio’s phase 3 IB1001-303 phase 3 data announced earlier this year.
Open in Who Shared Issue with article?

Europe's CHMP endorses slew of new medicines, including new offerings from Novo and AZ

|
By Donavyn Coffey Verified
| Fierce Pharma Verified
European drug regulators just wrapped another stack of reviews, and the EU bloc now has a sizeable list of likely new treatments to show for it. The European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has signed off on eight new medicines, two biosimilars and two generics, while also recommending label extensions for 11 other therapies.
Open in Who Shared Issue with article?
See all 298 licensed articles (417 Total)